Mohs microscopic surgery and image-guided superficial radiation therapy (IG-SRT) demonstrate high cure rates for non-melanoma ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

A team of researchers have identified a fundamental mechanism that links the 24-hour circadian cycle to the precise repair of DNA breaks. This study, conducted by researchers from the Andalusian ...

A team of researchers from the Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER) and the University ...

After James Van Der Beek shared that he was auctioning his treasures to pay for cancer treatment, Paul Walter Hauser ...

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

Abstract: Modern state-of-the-art Very Large Scale Integration (VLSI) circuits, such as Static Random-Access Memory (SRAM) covers a greater part of the chip area. As technology scales down and moves ...

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point for two distinct therapeutic pathways: Hodgkin’s lymphoma (HL) and ...

Integration of targeted therapies and immunotherapies offers new hope, enhancing survival rates and quality of life. Patients with mantle cell lymphoma experienced better survival rates when treated ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...